Dr. Anthony Fauci, Director at the National Institute of Allergy and Infectious Diseases, delivers remarks during a press briefing with Press Secretary Jen Psaki at the White House in Washington, U.S., April 13, 2021.
Tom Brenner | Reuters
White House chief medical advisor Dr. Anthony Fauci told CNBC on Tuesday he fully expects the coronavirus vaccines from Pfizer, Moderna and Johnson & Johnson will receive full approval from U.S. drug regulators.
“The data are about as good as it gets. … I would be astounded if these vaccines, namely the mRNA and the J&J, didn’t get full approval,” Fauci said on “Squawk Box.”
All three Covid vaccines are currently authorized for distribution in the U.S. on and emergency basis, but none of them have received full approval from the Food and Drug Administration. Full approval would allow the drugmakers to market the shots directly to consumers and give employers more flexibility in mandating them.
Pfizer and Moderna’s two-dose vaccines use mRNA technology, while J&J’s single-shot vaccine uses an adenovirus.
More than 184 million people in the U.S., or 55.5% of the population, are at least partially inoculated against Covid, according to CDC data. Nearly 160 million people, or 48% of the population, are fully vaccinated.
“Even though we are still under an emergency use authorization, it’s a bit different than other emergency use authorizations, which usually are granted with not nearly as much positive data as we have for these products,” Fauci said.
“The efficacy or the effectiveness in the real world is unquestioned, so we’re going to get a full approval,” he added. “The question is, it’s just going to take a little bit more time.”
Fauci’s appearance on CNBC comes one day after U.S. health officials, including Fauci, met with representatives from vaccine maker Pfizer to discuss the potential need for Covid booster shots.
Pfizer has said it sees signs that immunity from its two-dose vaccine declines over time and intends to pursue authorization for a booster shot. The company also is developing a booster meant to combat the highly contagious delta variant.
The FDA and Centers for Disease Control and Prevention have publicly pushed back on Pfizer’s case for a third dose, releasing a joint statement last week that said people who are fully vaccinated do not need a supplemental shot right now.